Lifeworks Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.7% during the second quarter, Holdings Channel reports. The institutional investor owned 10,001 shares of the company’s stock after acquiring an additional 67 shares during the quarter. Eli Lilly and Company comprises about 2.0% of Lifeworks Advisors LLC’s investment portfolio, making the stock its 11th biggest position. Lifeworks Advisors LLC’s holdings in Eli Lilly and Company were worth $4,690,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. Wellington Management Group LLP raised its holdings in shares of Eli Lilly and Company by 1.6% in the first quarter. Wellington Management Group LLP now owns 20,324,267 shares of the company’s stock valued at $6,979,760,000 after buying an additional 314,349 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Eli Lilly and Company by 533,336.4% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,059,681 shares of the company’s stock valued at $8,938,609,000 after buying an additional 19,056,108 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 1.1% in the first quarter. Geode Capital Management LLC now owns 14,867,424 shares of the company’s stock valued at $5,094,159,000 after buying an additional 159,964 shares during the last quarter. Morgan Stanley raised its holdings in shares of Eli Lilly and Company by 44.1% in the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after buying an additional 3,691,436 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $3,416,206,000. Institutional investors and hedge funds own 81.38% of the company’s stock.
Insiders Place Their Bets
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $605.44, for a total transaction of $130,169,600.00. Following the completion of the transaction, the insider now owns 99,768,810 shares of the company’s stock, valued at approximately $60,404,028,326.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction on Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total value of $130,169,600.00. Following the completion of the transaction, the insider now directly owns 99,768,810 shares of the company’s stock, valued at $60,404,028,326.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the completion of the transaction, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The disclosure for this sale can be found here. Insiders sold a total of 907,655 shares of company stock valued at $21,078,714,805 in the last quarter. 0.13% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $510.00 to $600.00 and gave the stock an “overweight” rating in a report on Wednesday, August 9th. Morgan Stanley boosted their price objective on Eli Lilly and Company from $640.00 to $673.00 and gave the stock an “overweight” rating in a report on Wednesday, October 11th. Jefferies Financial Group raised Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $408.00 to $615.00 in a report on Tuesday, August 8th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a report on Wednesday, August 9th. Finally, Bank of America boosted their price objective on Eli Lilly and Company from $600.00 to $700.00 in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $555.83.
Check Out Our Latest Report on LLY
Eli Lilly and Company Stock Up 1.3 %
Shares of LLY traded up $7.44 on Tuesday, hitting $584.09. The company’s stock had a trading volume of 393,581 shares, compared to its average volume of 3,027,417. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. The firm’s fifty day moving average price is $566.19 and its 200-day moving average price is $482.74. Eli Lilly and Company has a fifty-two week low of $309.20 and a fifty-two week high of $629.97. The firm has a market capitalization of $554.47 billion, a price-to-earnings ratio of 80.20, a P/E/G ratio of 3.45 and a beta of 0.33.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The firm had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. During the same quarter in the prior year, the firm posted $1.25 EPS. The business’s revenue was up 28.1% on a year-over-year basis. On average, equities research analysts expect that Eli Lilly and Company will post 6.65 EPS for the current year.
Eli Lilly and Company Profile
(Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Further Reading
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.
